Comparative Pharmacology
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE MALEATE AND GLIMEPIRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUETACT versus ROSIGLITAZONE MALEATE AND GLIMEPIRIDE.
DUETACT vs ROSIGLITAZONE MALEATE AND GLIMEPIRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUETACT is a fixed-dose combination of pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor-gamma (PPAR-γ), and glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Rosiglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Glimepiride is a sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Initial dose: 30 mg pioglitazone/2 mg glimepiride orally once daily; titrate based on glycemic control; maximum dose: 45 mg pioglitazone/8 mg glimepiride daily.
Oral, initial dose 4 mg rosiglitazone/1 mg glimepiride once daily, titrate based on glycemic response; maximum dose 8 mg rosiglitazone/4 mg glimepiride once daily.
None Documented
None Documented
Pioglitazone: terminal half-life 3-7 hours (parent drug), 16-24 hours (active metabolites); clinical context: once-daily dosing sufficient due to active metabolites. Glimepiride: terminal half-life 5-8 hours; clinical context: supports once- or twice-daily dosing in type 2 diabetes.
Rosiglitazone: 3-4 hours. Glimepiride: 5-9 hours. Clinically, twice-daily dosing for rosiglitazone and once-daily for glimepiride.
Pioglitazone is primarily excreted in feces (55%) as metabolites, with renal excretion accounting for 30% (primarily as metabolites and <5% unchanged). Glimepiride is excreted in urine (60% as metabolites, ~25% unchanged) and feces (40% as metabolites).
Rosiglitazone: primarily hepatic metabolism with <1% excreted unchanged in urine; fecal (23%) and urinary (64%) elimination as metabolites. Glimepiride: ~60% excreted in urine as metabolites, ~40% in feces as metabolites.
Category C
Category A/B
Thiazolidinedione/Sulfonylurea Combination
Thiazolidinedione